UPDATE: Rodman & Renshaw Upgrades Abiomed Inc from Market Underperform to Market Perform

Rodman & Renshaw has published a report on Abiomed Inc ABMD upgrading the stock as it reached the PT. In the report, Rodman & Renshaw wrote, "We are upgrading ABMD to a Market Perform rating. Our earlier rating was a Market UnderPerform with a $10 PT. ABMD stock recently hit our PT and since has moved slightly up. Our ratings change is simply a reflection of the stock price move and nothing to do with fundamentals." Rodman & Renshaw upgraded Abiomed from Market Underperform to Market Perform with a price target of $10.00. Rodman & Renshaw closed Friday at $11.66.